Biotechnology - Licensing, AstraZeneca

Filter

Current filters:

LicensingAstraZeneca

Popular Filters

AstraZeneca in deal with Immunocore to develop novel cancer therapies

AstraZeneca in deal with Immunocore to develop novel cancer therapies

08-01-2014

UK privately-held biotech firm Immunocore has signed an oncology research collaboration and licensing…

AstraZenecaBiotechnologyImmunocoreLicensingMedImmuneOncologyResearch

AstraZeneca collaborates with TARIS Biomedical for improved bladder cancer treatments

AstraZeneca collaborates with TARIS Biomedical for improved bladder cancer treatments

17-10-2013

Privately-held US biotech firm TARIS Biomedical has entered into a research collaboration with Anglo-Swedish…

AstraZenecaBiotechnologyLicensingOncologyResearchTARIS Biomedical

AstraZeneca to fork out $815 million for rights to anemia drug candidate

31-07-2013

In yet another move to boost its R&D pipeline, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered…

Asia-PacificASP1517Astellas PharmaAstraZenecaBiotechnologyFG-4592FibroGenLicensingNephrology and HepatologyNorth AmericaPharmaceuticalResearch

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research

17-06-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

Evotec acquires Cell Culture Service GmbH; expands deal with AstraZeneca

07-01-2013

German biotech firm Evotec (EVT: TecDAX) has acquired all the shares in Cell Culture Service GmbH (CCS),…

AstraZenecaBiotechnologyCell Culture Service GmbHDiabetesEvotecLicensingMedImmuneMergers & AcquisitionsPharmaceutical

AstraZeneca aligns with Regulus for microRNA therapeutics

16-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US biotech firm Regulus Therapeutics have signed…

AstraZenecaBiotechnologyCardio-vascularLicensingMetabolicsPharmaceuticalRegulus Therapeutics

AstraZeneca and Bristol-Myers complete diabetes alliance expansion; Lilly revises guidance

10-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that, following Bristol-Myers Squibb's…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbDiabetesEli LillyFinancialLicensingPharmaceutical

Pharma partnering dollars continue to decline, Burrill & Co reports

06-08-2012

The recent $3.4 billion partnering agreement announced in July between US pharma company Bristol-Myers…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbFinancialGlaxoSmithKlineHuman Genome SciencesLicensingMarkets & Marketing

Deal-making opportunities for big pharma and biotech firms

15-04-2012

Big pharmaceutical companies are looking to partner with biotechnology companies for the innovation required…

AmgenAstraZenecaBiotechnologyLicensingPharmaceutical

AstraZeneca collaborates with Amgen on five MAbs

03-04-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Amgen (Nasdaq: AMGN), the world's largest independent…

AmgenAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseasesLicensingPharmaceutical

AgonOx partners with AstraZeneca unit for development of OX40 agonists in cancer therapy

02-11-2011

USA-based AgonOx has entered into an exclusive global partnership with MedImmune, the global biologics…

AgonOxAstraZenecaBiotechnologyLicensingMedImmuneOncologyPharmaceuticalResearch

Company Spotlight

ImmunoGen

ImmunoGen

Back to top